Key result
Early AVR cuts MACE ~59% versus clinical surveillance in asymptomatic severe aortic stenosis.
Why the study?
The optimal timing of aortic valve replacement in patients with asymptomatic severe aortic stenosis remains uncertain.
Does early aortic valve replacement reduce major adverse cardiovascular events and mortality in patients with asymptomatic severe aortic stenosis compared to clinical surveillance?
Meta-Analysis (n=3,086)
Yes
Does early aortic valve replacement reduce major adverse cardiovascular events and mortality in patients with asymptomatic severe aortic stenosis compared to clinical surveillance?
Odds Ratio: 0.41 (95% CI 0.29–0.59)
Absolute Event Rate: 17.9% vs 33.7%
Absolute Risk Reduction: 15.8%
Number Needed to Treat: 6
p-value: p=<0.001
Early aortic valve replacement in asymptomatic severe aortic stenosis significantly reduces MACE, mortality, and heart failure hospitalizations compared to clinical surveillance, though it increases the risk of major vascular bleeding.
Supports early AVR consideration in asymptomatic severe AS; extends mixed RCT/observational data but needs dedicated large trials.
Background The optimal timing of aortic valve replacement (AVR) in patients with asymptomatic severe aortic stenosis (AS) remains uncertain. The aim of this study was to evaluate the efficacy and safety of early AVR compared to clinical surveillance (CSV) in patients with asymptomatic severe AS. Methods We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus through August 2025 for studies that compared early AVR with conservative management in asymptomatic patients with severe AS. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using random-effects models. Results Eight studies including four randomized controlled trials and four propensity-matched observational studies, enrolling 3,086 patients, of whom 1,539 (49.9%) underwent early AVR were included. Compared with CSV, AVR was associated with significant reduction in MACE (OR: 0.41, 95% CI: 0.29–0.59; P < 0.001), all-cause mortality (OR: 0.59, 95% CI: 0.39–0.88; P = 0.011), cardiovascular mortality (OR: 0.49, 95% CI: 0.35–0.69; P < 0.001), hospitalization for heart failure (OR 0.36, 95% CI 0.20–0.65; P < 0.001), and sudden death (OR: 0.51, 95% CI: 0.29–0.88; P = 0.015). Major vascular bleeding was more frequent in the early AVR group than in the conservative surveillance group (OR: 1.75, 95% CI: 1.05–2.92; P = 0.032). The risk of myocardial infarction, stroke, pacemaker implantation, or infective endocarditis were similar between groups. Conclusion In patients with asymptomatic severe aortic stenosis, an early AVR strategy was associated with reduced heart failure hospitalization, favorable composite and procedural safety outcomes compared with CSV. Although a survival benefit was observed in pooled analyses, this was not consistently demonstrated in randomized trials. These findings support a more individualized approach to the timing of intervention. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/ CRD420251135500.
No takes yet. Share an insight, caveat, or question.
Adamu et al. (2026) conducted a meta-analysis in Asymptomatic severe aortic stenosis (n=3,086). Early aortic valve replacement vs. Clinical surveillance was evaluated on Major adverse cardiovascular events (MACE) (OR 0.41, 95% CI 0.29-0.59, p=<0.001). Early aortic valve replacement significantly reduced major adverse cardiovascular events (OR 0.41) compared to clinical surveillance in patients with asymptomatic severe aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: